Vanguard Group Inc. Sells 64,339 Shares of Integra LifeSciences Holdings Corporation $IART

Key Points

• Vanguard Group Inc. reduced its stake in Integra LifeSciences Holdings Corporation by 0.8%, owning approximately 7.5 million shares, valued at about $165 million as of the latest SEC filing.
• Integra LifeSciences reported a quarterly revenue of $415.61 million and earnings per share (EPS) of $0.45, surpassing analysts' expectations of $0.43 EPS.
• Several analysts have downgraded Integra LifeSciences' stock price targets, with JPMorgan reducing it from $24 to $12, indicating a negative outlook.

Vanguard Group Inc. lessened its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 0.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,516,628 shares of the life sciences company's stock after selling 64,339 shares during the period. Vanguard Group Inc. owned about 9.73% of Integra LifeSciences worth $165,291,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its stake in shares of Integra LifeSciences by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company's stock worth $9,542,000 after buying an additional 10,492 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Integra LifeSciences during the 1st quarter worth about $251,000. Victory Capital Management Inc. boosted its stake in shares of Integra LifeSciences by 1,067.6% during the 1st quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company's stock worth $3,254,000 after buying an additional 135,308 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Integra LifeSciences by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock worth $872,000 after buying an additional 1,437 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Integra LifeSciences by 3,595.1% during the 1st quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock worth $5,140,000 after buying an additional 22,721 shares during the last quarter. Institutional investors own 84.78% of the company's stock.

Wall Street Analysts Forecast Growth

IART has been the subject of a number of recent research reports. Wells Fargo & Company reduced their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, JMP Securities reduced their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, Integra LifeSciences has an average rating of "Reduce" and a consensus price target of $18.63.

Integra LifeSciences Stock Performance

Shares of IART stock traded up $0.49 on Tuesday, reaching $14.76. The stock had a trading volume of 1,692,688 shares, compared to its average volume of 1,488,786. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. The firm's 50-day moving average is $12.86 and its two-hundred day moving average is $16.23. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -2.26, a P/E/G ratio of 0.80 and a beta of 1.16. Integra LifeSciences Holdings Corporation has a 12 month low of $11.06 and a 12 month high of $27.13.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The company had revenue of $415.61 million for the quarter, compared to analysts' expectations of $395.06 million. During the same period in the prior year, the firm earned $0.63 EPS. Integra LifeSciences's quarterly revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.